A number of cytokine pathways are important in the disease process of SLE, and several biological agents for SLE have been developed that target different cytokines or their receptors. This Review discusses the rationale for the use of anticytokine therapies in SLE, reviews the different agents tested to date, and presents future directions for therapy.
- Lars Rönnblom
- Keith B. Elkon